Voyager’s CSO Dinah Sah to Retire, Omar Khwaja Expands Role

Dinah Sah is retiring from her position as chief scientific officer of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]). In her place, the Cambridge, MA-based gene therapy developer said that Chief Medical Officer Omar Khwaja will take on an expanded role as chief medical officer and head of research and development. The changes will happen June 28, but Sah will continue to serve as a consultant to the company and she will join its scientific advisory board. Voyager is developing gene therapies for neurological disorders including Alzheimer’s and Parkinson’s.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan